These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 16432179)

  • 1. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
    Bader AG; Kang S; Vogt PK
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
    Kang S; Bader AG; Vogt PK
    Proc Natl Acad Sci U S A; 2005 Jan; 102(3):802-7. PubMed ID: 15647370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
    Ikenoue T; Kanai F; Hikiba Y; Obata T; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Tateishi K; Asaoka Y; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2005 Jun; 65(11):4562-7. PubMed ID: 15930273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
    Zhao JJ; Liu Z; Wang L; Shin E; Loda MF; Roberts TM
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18443-8. PubMed ID: 16339315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
    Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
    Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
    Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
    Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic signaling of class I PI3K isoforms.
    Denley A; Kang S; Karst U; Vogt PK
    Oncogene; 2008 Apr; 27(18):2561-74. PubMed ID: 17998941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
    Ross RL; Askham JM; Knowles MA
    Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare cancer-specific mutations in PIK3CA show gain of function.
    Gymnopoulos M; Elsliger MA; Vogt PK
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5569-74. PubMed ID: 17376864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human tumor mutants in the p110alpha subunit of PI3K.
    Liu Z; Roberts TM
    Cell Cycle; 2006 Apr; 5(7):675-7. PubMed ID: 16627990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions.
    Hao Y; Wang C; Cao B; Hirsch BM; Song J; Markowitz SD; Ewing RM; Sedwick D; Liu L; Zheng W; Wang Z
    Cancer Cell; 2013 May; 23(5):583-93. PubMed ID: 23643389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene of the month: PIK3CA.
    Lai K; Killingsworth MC; Lee CS
    J Clin Pathol; 2015 Apr; 68(4):253-7. PubMed ID: 25688137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
    Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
    Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
    Xia C; Meng Q; Cao Z; Shi X; Jiang BH
    J Cell Physiol; 2006 Oct; 209(1):56-66. PubMed ID: 16775835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase.
    Kang S; Denley A; Vanhaesebroeck B; Vogt PK
    Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1289-94. PubMed ID: 16432180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional differences between two classes of oncogenic mutation in the PIK3CA gene.
    Chaussade C; Cho K; Mawson C; Rewcastle GW; Shepherd PR
    Biochem Biophys Res Commun; 2009 Apr; 381(4):577-81. PubMed ID: 19233141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription factor Ets-1 regulates fibroblast growth factor-1-mediated angiogenesis in vivo: role of Ets-1 in the regulation of the PI3K/AKT/MMP-1 pathway.
    Forough R; Weylie B; Collins C; Parker JL; Zhu J; Barhoumi R; Watson DK
    J Vasc Res; 2006; 43(4):327-37. PubMed ID: 16682805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.